

1'-Methylacenaphthylene-1(2H)-spiro-2'-pyrrolidine-3'-spiro-2''(3''H)-carbazole-2,1''(4''H)-dione**B. K. Satis Kumar,^a D. Gayathri,^b
D. Velmurugan,^{b*} K. Ravikumar^c
and G. Periyasami^d**^aDepartment of Physics, Presidency College, Chennai 600 005, India, ^bDepartment of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600 025, India, ^cLaboratory of X-ray Crystallography, Indian Institute of Chemical Technology, Hyderabad 500 007, India, and ^dDepartment of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India


Correspondence e-mail: d_velu@yahoo.com

Key indicatorsSingle-crystal X-ray study
 $T = 293$ K
Mean $\sigma(\text{C}-\text{C}) = 0.002$ Å
 R factor = 0.051
 wR factor = 0.146
Data-to-parameter ratio = 17.5For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the title compound, $\text{C}_{33}\text{H}_{26}\text{N}_2\text{O}_2$, the pyrrolidine ring adopts an envelope conformation with the N atom deviating by 0.600 (1) Å from the plane of the other four atoms. The molecule is stabilized by weak intramolecular C—H···O interactions and the crystal packing is stabilized by N—H···O and C—H···O hydrogen bonds, generating centrosymmetric dimers of $R_2^2(10)$ and $R_2^2(14)$ rings.

Comment

Spiro-indole-pyrrolidine ring systems have acquired a special place in the heterocyclic field as this is a frequently encountered structural motif in many pharmacologically relevant alkaloids (Amal Raj *et al.*, 2003). It has been shown that functionalized pyrrolidines inhibit γ -mannosidase activity and growth of human glioblastoma and melanoma cells (Fiaux *et al.*, 2005). Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines (Morais *et al.*, 2006).



The bond lengths and bond angles in the title compound, (I) (Table 1), are comparable to similar structures determined previously (Satis Kumar *et al.*, 2006). The sum of the bond angles around N1 atom (336.9°) indicates sp^3 hybridization. Atom O1 deviates by 0.069 (1) Å from the C6/C7/C16/C15/C1 plane. The pyrrolidine ring (N1/C1–C4) adopts an envelope conformation, with atom N1 deviating by 0.600 (1) Å from the other atoms in the ring. The acenaphthene unit is planar with a dihedral angle between the two benzene rings of $1.6(1)^\circ$; the dihedral angles between the benzene rings (C7–C11/C16) and (C11–C16) and the five-membered ring are $0.5(1)$ and $1.8(1)^\circ$, respectively. The dihedral angle between the planar pyrrole (C19/C20/C25/N2/C26) and the C20–C25 benzene ring is $2.6(1)^\circ$, while that between the two C20–C25 and C28–C33 benzene rings is $89.6(1)^\circ$. The puckering parameters (Cremer

Received 9 January 2007
Accepted 17 January 2007




Figure 1
The molecular structure of the title compound, (I), showing 30% probability displacement ellipsoids.




Figure 2
The molecular packing of (I), viewed down the *a* axis. Hydrogen bonds are shown as dashed lines. For the sake of clarity, H atoms not involved in hydrogen bonding have been omitted.

& Pople, 1975) and the smallest displacement asymmetry parameters (Nardelli, 1983) for the pyrrolidine ring are $q_2 = 0.411$ (2), $\varphi = 178.9$ (2)° and $\Delta_s(N_1) = 2.1$ (1).

The molecule is stabilized by weak intramolecular C—H···O interactions and the crystal packing is stabilized by intermolecular N—H···O and C—H···O interactions. In the N—H···O and C—H···O hydrogen bonds, atoms N2 and C14 act as donors to O2(−*x*, 1 − *y*, 1 − *z*), generating centrosymmetric dimers of $R_2^2(10)$ and $R_2^2(14)$ rings.

Experimental

A mixture of acenaphthaquinone (0.18 g, 1 mmol), sarcosine (0.89 g, 1 mmol) and 2-benzylidene-3,4-tetrahydro-1-ketocarbazole (0.31 g, 1 mmol) was refluxed in 1,4-dioxane–methanol (1:1) for 6 h. The reaction was monitored by thin-layer chromatography and after

completion of the reaction, the solvent was removed under reduced pressure. The crude product was subjected to column chromatography (silica gel, 100–200 mesh) using hexane–EtOAc (8:2) as eluent. The pure compound was recrystallized from EtOAc.

Crystal data

$C_{33}H_{26}N_2O_2$
 $M_r = 482.56$
Monoclinic, $P2_1/c$
 $a = 9.2279$ (6) Å
 $b = 21.9358$ (13) Å
 $c = 12.7618$ (8) Å
 $\beta = 103.163$ (1)°
 $V = 2515.4$ (3) Å³

$Z = 4$
 $D_x = 1.274$ Mg m^{−3}
Mo $K\alpha$ radiation
 $\mu = 0.08$ mm^{−1}
 $T = 293$ (2) K
Block, yellow
0.24 × 0.22 × 0.21 mm

Data collection

Bruker SMART APEX CCD area-detector diffractometer
 ω scans
Absorption correction: none
28499 measured reflections

5873 independent reflections
4870 reflections with $I > 2\sigma(I)$
 $R_{int} = 0.018$
 $\theta_{max} = 28.0^\circ$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.051$
 $wR(F^2) = 0.146$
 $S = 1.00$
5873 reflections
335 parameters
H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0882P)^2 + 0.4529P]$
where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{max} < 0.001$
 $\Delta\rho_{max} = 0.33$ e Å^{−3}
 $\Delta\rho_{min} = -0.19$ e Å^{−3}

Table 1

Selected geometric parameters (Å, °).

C1—N1	1.471 (2)	C3—C4	1.531 (2)
C1—C15	1.526 (2)	C4—N1	1.453 (2)
C1—C6	1.582 (2)	C5—N1	1.458 (2)
C1—C2	1.585 (2)	C6—O1	1.216 (2)
C2—C27	1.543 (2)	C25—N2	1.363 (2)
C2—C17	1.545 (2)	C26—N2	1.381 (2)
C2—C3	1.583 (2)	C27—O2	1.224 (2)
C3—C28	1.517 (2)		
C4—N1—C5	114.3 (1)	C5—N1—C1	115.6 (1)
C4—N1—C1	107.0 (1)		

Table 2

Hydrogen-bond geometry (Å, °).

<i>D</i> —H··· <i>A</i>	<i>D</i> —H	H··· <i>A</i>	<i>D</i> ··· <i>A</i>	<i>D</i> —H··· <i>A</i>
N2—H2···O2 ⁱ	0.86	2.27	2.929 (2)	133
C3—H3···O2	0.98	2.23	2.779 (2)	115
C4—H4B···O1	0.97	2.48	3.058 (2)	118
C14—H14···O2 ⁱ	0.93	2.60	3.325 (2)	135
C17—H17A···O1	0.97	2.51	3.187 (2)	127
C33—H33···O1	0.93	2.57	3.391 (2)	148

Symmetry code: (i) −*x*, −*y* + 1, −*z* + 1.

All H atoms were refined using a riding model, with C—H = 0.93 Å and $U_{iso}(H) = 1.2U_{eq}(C)$ for aromatic, C—H = 0.98 Å and $U_{iso}(H) = 1.2U_{eq}(C)$ for CH, C—H = 0.97 Å and $U_{iso}(H) = 1.2U_{eq}(C)$ for CH₂, C—H = 0.96 Å and $U_{iso}(H) = 1.5U_{eq}(C)$ for CH₃, and N—H = 0.86 Å and $U_{iso}(H) = 1.2U_{eq}(N)$ for NH hydrogens.

Data collection: *SMART* (Bruker, 2001); cell refinement: *SAINT* (Bruker, 2001); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics:

PLATON (Spek, 2003); software used to prepare material for publication: *SHELXL97* and *PARST* (Nardelli, 1995).

DG thanks CSIR, India, for the award of a Senior Research Fellowship. DV thanks DST, India, for a major research project. The Department of Science & Technology (DST-FIST), Government of India, is acknowledged by DV for providing facilities to the department.

References

- Amal Raj, A., Raghunathan, R., Sridevi Kumari, M. R. & Raman, N. (2003). *Bioorg. Med. Chem.* **11**, 407–409.
- Braker (2001). *SMART*. (Version. 5.625/NT/2000) and *SAINT*. (Version 6.28a). Bruker AXS Inc., Madison, Wisconsin, USA.
- Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
- Fiaux, H., Popowycz, F., Favre, S., Schutz, C., Vogel, P., Gerber-Lemaire, S. & Juillerat-Jeanneret, L. (2005). *J. Med. Chem.* **48**, 4237–4246.
- Kumar, B. K. S., Gayathri, D., Velmurugan, D., Ravikumar, K. & Periyasami, G. (2006). *Acta Cryst.* **E62**, o5075–o5077.
- Morais, C., Pat, B., Gobe, G., Johnson, D. W. & Healy, H. (2006). *Nephrol. Dial. Transplant.* **23**, 1–12.
- Nardelli, M. (1983). *Acta Cryst.* **C39**, 1141–1142.
- Nardelli, M. (1995). *J. Appl. Cryst.* **28**, 659.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.